Your search history is turned on.
Date: October 20, 2020 Jurisdictions: Alberta, British Columbia, Ontario
Press Release COTINGA PHARMACUETICALS PROVIDES UPDATE ON FILING OF ANNUAL RESULTS Toronto, ON and Boston, MA October 15, 2020): Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (Cotinga or the Company), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer. Cotinga did not fi...
Date: March 19, 2019 Jurisdictions: Alberta, British Columbia, Ontario
COTINGA PHARMACUETICALS PROVIDES SCIENTIFIC AND BUSINESS UPDATE AT ANNUAL GENERAL MEETING AND ANNOUNCES UNIT OFFERING Highlighted progress and continued commitment to advancing the clinical development of lead asset COTI-2 in multiple oncology indications Toronto, ON and Boston, MA (March 19, 2019): Cotinga Pharmac...
Date: February 26, 2019 Jurisdictions: Alberta, British Columbia, Ontario
Page | 2 COTINGA PHARMACEUTICALS INC. Registered Office Toronto, Ontario NOTICE OF THE 2018 ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS Notice is hereby given that the 2018 Annual General and Special Meeting of the holders of common shares (the Shareholders) of Cotinga Pharmaceuticals Inc.. (the Company) will be held in McMilla...
Security Class Holder Account Number Form of Proxy - Annual General and Special Meeting to be held on Tuesday, March 19, 2019 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of their choice, who need not be a holder, to attend and act on their behalf at ...
Page | 1 February 20, 2019 Dear Fellow Shareholder: On behalf of the management team and the Board of Directors, it is our pleasure to invite you to attend this years Annual General and Special Meeting of Shareholders (the Meeting) of Cotinga Pharmaceuticals Inc. The Meeting will be held on Tuesday, March 19, 2019 at 10.00 a...
Page | 1 COTINGA PHARMACEUTICALS DOSES FIRST PATIENT IN SECOND COHORT OF PHASE 1B/2A COMBINATION TRIAL OF COTI-2 IN SOLID TUMORS Independent Dose Escalation Committee (DEC) recommends continuing the study at an increased dose Toronto, ON and Boston, MA (February 26, 2019): Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (Co...
Date: January 29, 2019 Jurisdictions: Alberta, British Columbia, Ontario
Page | 1 COTINGA PHARMACEUTICALS DOSES COHORT 1 PATIENTS WITH COMBINATION THERAPY IN PHASE 1B/2A TRIAL OF COTI-2 Toronto, ON and Boston, MA (January 29, 2019): Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (Cotinga or the Company), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of ca...
Date: January 18, 2019 Jurisdictions: All jurisdictions
Date: January 18, 2019 530-8th Avenue SW, 6th floor Calgary AB, T2P 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: COTINGA PHARMACEUTICALS INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General and S...
Date: January 15, 2019 Jurisdictions: Alberta, British Columbia, Ontario
Page | 1 COTINGA PHARMACEUTICALS DOSES FIRST PATIENT WITH COMBINATION THERAPY IN PHASE 1B/2A TRIAL OF COTI-2 Cohort 1 of COTI-2 plus cisplatin combination trial is fully enrolled at MD Anderson Toronto, ON and Boston, MA (January 15, 2019): Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (Cotinga or the Company) , a clinical-stage ph...
Date: January 8, 2019 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - 190108 COT NR Page|1 COTINGAPHARMACEUTICALSENROLLSTWOPATIENTSFORCOMBINATION THERAPYINPHASE1B/2ATRIALOFCOTI2 Toronto, ON and Boston, MA (January 8, 2019): Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (Cotinga or the Company) , a clinicalstage pharmaceutical company advanc...